EWA
BCRX icon

EverSource Wealth Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

EverSource Wealth Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.6K Buy
2,558
+1,552
+154% +$14K ﹤0.01% 2256
2026
Q1 		$9.58K Buy
1,006
+442
+78% +$3.43K ﹤0.01% 2941
2025
Q4 		$4.4K Sell
564
-518
-48% -$3.75K ﹤0.01% 3170
2025
Q3 		$8.21K Sell
1,082
-1,183
-52% -$9.85K ﹤0.01% 2923
2025
Q2 		$20.3K Buy
2,265
+1,195
+112% +$11.1K ﹤0.01% 2276
2025
Q1 		$8.03K Buy
1,070
+920
+613% +$7.42K ﹤0.01% 2238
2024
Q4 		$1.13K Buy
150
+50
+50% +$380 ﹤0.01% 2924
2024
Q3 		$760 Hold
100
– – ﹤0.01% 2776
2024
Q2 		$728 Hold
100
– – ﹤0.01% 2801
2024
Q1 		$413 Hold
100
– – ﹤0.01% 2756
2023
Q4 		$599 Hold
100
– – ﹤0.01% 2493
2023
Q3 		$708 Hold
100
– – ﹤0.01% 2322
2023
Q2 		$704 Hold
100
– – ﹤0.01% 2292
2023
Q1 		$834 Sell
100
-1,855
-95% -$17.9K ﹤0.01% 2151
2022
Q4 		$22.4K Sell
1,955
-1,000
-34% -$12.5K ﹤0.01% 1028
2022
Q3 		$38K Hold
2,955
– – 0.01% 706
2022
Q2 		$32K Hold
2,955
– – 0.01% 708
2022
Q1 		$48K Hold
2,955
– – 0.01% 469
2021
Q4 		$41K Buy
+2,955
New +$39.1K 0.01% 460

Other funds holding BCRX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

EverSource Wealth Advisors's BCRX Position: Q2 2026 in Review

EverSource Wealth Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 154% in Q2 2026, buying an estimated $14K and bringing the position to 2,558 shares worth $25.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2256.

EverSource Wealth Advisors first reported a position in BCRX in Q4 2021 and has held it in 19 quarters since. The position peaked at $48K in Q1 2022. 95 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • EverSource Wealth Advisors held 2,558 shares of BioCryst Pharmaceuticals worth $25.6K as of Q2 2026.
  • EverSource Wealth Advisors bought 1,552 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $14K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2256 holding.
  • EverSource Wealth Advisors first reported a position in BioCryst Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • EverSource Wealth Advisors's BioCryst Pharmaceuticals position peaked at $48K in Q1 2022.
  • 95 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.